Trikafta, made by Vertex Pharmaceuticals, is, as its name suggests, a combination of three drugs. It works for 90 percent of patients with cystic fibrosis, and will be priced at $311,000 per year.

Listed below are the charts and positions for Trikafta/Kaftrio in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Trikafta/Kaftrio. GlobalData provides trusted ...

Vertex Pharmaceuticals today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has granted consent for the expanded use of ...